Covalent attachment of ubiquitin to proteins by sequential actions of ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2) and ubiquitin ligase (E3) is an important cellular regulatory mechanism 1 . There are three classes of E3s (HECT, RING and U-box 2,3 ) that transfer ubiquitin to the substrate and thus have a pivotal role in determining substrate fate. Of these, RING E3s make up the largest family, which can be subdivided into two classes: single-subunit and multiprotein complex. RING E3s function by recruiting an E2 that is thioesterified with ubiquitin (E2~ubiquitin) through the RING domain and substrate by means of a protein-protein interaction domain. The thioesterified ubiquitin is then transferred directly from the E2 to a lysine side chain on the substrate. Much of our understanding of the regulation of RING E3s comes from studies of multiprotein RING complexes such as cullin-RING ligases (CRLs) 4,5 . Although both classes consist of about 300 members in the human genome 5, 6 , the mechanisms of single-subunit RING E3 regulation remain poorly understood.
a r t i c l e s
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Cbls (c-Cbl, Cbl-b and Cbl-c) are single-subunit RING E3s that negatively regulate a host of proteins by promoting their ubiquitination and subsequent degradation by the proteasome or through endocytosis [7] [8] [9] [10] [11] . Independent of their E3 activity, they also function as adaptors in a variety of diverse biological processes, such as insulin signaling, bone resorption and activation of mitogen-activated protein kinases 9, 10 . Cbls act as both positive and negative regulators in the signal transduction of RTKs 10 : they propagate signals downstream of activated RTKs as adaptors and simultaneously ubiquitinate and promote degradation of the same RTKs as E3s. To carry out both of these roles, Cbls have evolved several protein-protein interaction modules. All Cbls share a highly conserved N-terminal SH2-containing tyrosine kinase-binding domain (TKBD), an LHR and a RING domain, followed by a variable proline-rich region. In addition, c-Cbl and Cbl-b also contain a highly variable C-terminal extension involved in dimerization, binding of ubiquitinated proteins and substrate recruitment following phosphorylation 9, 12, 13 . The TKBD mediates substrate specificity by binding to proteins containing phosphotyrosine motifs commonly found in RTKs or tyrosine kinases such as Zap-70 kinase 8, 14, 15 , whereas the proline-rich region recruits proteins containing an SH3 domain. The LHR and RING domain have central roles in recruiting E2s and in mediating target ubiquitination 7, 16 . Mutations within these regions, as observed in people with myeloproliferative diseases and oncogenic forms of c-Cbl such as v-Cbl, 70ZCbl and p95Cbl, abrogate the E3 activity of c-Cbl (refs. 17-24) .
Precise control of the E3 activity of Cbl is required to facilitate its dual E3 and adaptor functions. Phosphorylation of a conserved tyrosine residue (Tyr371 in c-Cbl) within the LHR regulates the E3 activity of Cbl (refs. 8,25,26) . Mass spectrometry studies show c-Cbl Tyr371 is phosphorylated in cells following epidermal growth factor (EGF) stimulation 27 , and mutational analyses also demonstrate this event following insulin stimulation 28 . In addition, biochemical studies with Cbl fragments comprising the TKBD, LHR and RING domain reveal that Cbls are more active ligases when they are phosphorylated 25, 26 , and mutation of c-Cbl Tyr371 abrogates RTK ubiquitination in vivo 8, [20] [21] [22] . c-Cbl Tyr371 has recently emerged as one of the frequently mutated residues found in people with myeloid neoplasms 24 .
Although these studies support a role for Tyr371 phosphoregulation of the ligase activity of c-Cbl, the existing structure of c-Cbl (ref. 16) does not explain how phosphorylation enhances ligase activity, as Tyr371 is buried in the LHR-TKBD interface. Phosphorylation would a r t i c l e s disrupt this interface and probably perturb the LHR-E2 interactions 16 . To understand how Tyr371 phosphorylation regulates the activity of c-Cbl, we determined three new crystal structures of human CBL (also known as C-CBL): native CBL, CBL bound to the ZAP-70 peptide (a TKBD substrate peptide) and CBL phosphorylated at Tyr371 in complex with the E2 UbcH5B and ZAP-70 peptide (referred to as nCBL, CBL−S and E2−pCBL−S, respectively). These structures and the existing structure of CBL bound to the E2 UbcH7 and ZAP-70 peptide 16 reveal marked conformational changes in the LHR and RING domain. In conjunction with biochemical analyses, we show that CBL adopts an autoinhibited conformation in which its E2-binding surface on the RING domain is occluded in a competitive manner to reduce E2 binding, thereby attenuating its ligase activity. Phosphorylated Tyr371 (pTyr371) activates the E3 activity of CBL by inducing marked LHR conformational changes that (i) enhance overall E2-binding affinity by abolishing autoinhibition and modifying the E2-binding surface and (ii) place the RING domain and E2 in proximity to the TKBD substrate. These properties are required for EGF receptor (EGFR) ubiquitination.
RESULTS

CBL structures reveal marked conformational changes
The structures of nCBL, CBL−S and E2−pCBL−S were determined using a CBL fragment (CBL ) containing the N-terminal TKBD, the LHR and the RING domain ( Fig. 1 and Table 1 ). For purposes of this discussion, the structural elements of the LHR are termed linkerloop 1 (LL1), linker-helix (LH) and linker-loop 2 (LL2) (Fig. 1a) . The TKBD is similar in all of our three structures and the structures of the TKBD alone or bound to the ZAP-70 peptide 15 (r.m.s. deviation is between 0.4−1.4 Å for Cα atoms). The RING domain is also similar (r.m.s. deviation is between 0.45−0.53 Å for Cα atoms). Notably, the LHR appears extremely flexible: none of our LHR conformations resemble each other or resemble the one observed in the existing structure of CBL bound to E2 and the ZAP-70 substrate peptide 16 (E2−CBL−S; Fig. 1d) , which results in marked changes in the orientation of the RING relative to the TKBD. In E2−CBL−S, the entire LHR packs against the TKBD; the catalytic cysteine of E2 is ~67 Å from the ZAP-70 peptide and faces away from the substrate-binding site. In the phosphorylated complex, LH is released from the TKBD, and the LHR undergoes ~180° rotation about LL1, reducing the gap between the catalytic cysteine of E2 and the ZAP-70 peptide to ~28 Å ( Fig. 1e and Supplementary Fig. 1a) .
nCBL (Fig. 1b) is more compact than E2−CBL−S; the RING-TKBD-LL2 interaction buries ~980 Å 2 of surface area. The LL1 and LH conformations are similar, but LL2 changes, which reorients the RING relative to the TKBD (Supplementary Fig. 1b) . Notably, in nCBL, the E2-binding surface on the RING domain is now facing the TKBD. Upon binding to the ZAP-70 peptide, LL2 assumes a new conformation, and the RING domain undergoes an ~70° rotation relative to that observed in nCBL, partially exposing the E2-binding surface on the RING domain ( Fig. 1c and Supplementary Fig. 1b) . Superposition of the RING domains from CBL−S and E2−CBL−S reveals a clash between E2 and the TKBD (Supplementary Fig. 1c) , suggesting that further conformational changes of LL2 and rotation of the RING domain are necessary to accommodate an E2 (Fig. 1d) .
CBL adopts autoinhibited and open conformations
In nCBL, the E2-binding surface on the RING domain directly contacts the TKBD in a manner that prevents E2 binding, revealing an autoinhibited conformation of the RING domain (Fig. 1b) , hereby referred to as 'closed' . Unexpectedly, the residues that maintain the closed conformation also engage in E2 binding, as shown in E2−CBL−S (Fig. 2a,b) . The closed RING conformation is stabilized by hydrophobic contacts involving Ile383, Trp408 and Phe418 from the RING domain and Leu219 and Met222 from the TKBD. In the structure of E2−CBL−S, Ile383, Trp408 and Phe418 bind directly to UbcH7, whereas Leu219 and Met222 assist Leu380 and Glu386 in creating a pocket to accommodate Arg5 of UbcH7. Numerous hydrogen bonds involving residues from the RING domain, TKBD and LHR also stabilize the closed conformation; these residues are similarly involved in E2 binding. Substrate binding and phosphorylation perturb the closed conformation ( Fig. 1; see below) . Binding of the TKBD substrate peptide induces slight movement within the TKBD and displaces the loop containing Phe271 ~4 Å toward LL2 (Fig. 2c) . This disrupts the LL2-RING interactions seen in the closed RING conformation and establishes a new hydrophobic interaction between Phe271 and Phe378 of LL2. These LL2 conformational changes rotate the RING domain into an open configuration. Structures of CBL's TKBD in complex with various phosphotyrosine substrate peptides show identical Phe271 displacement 29, 30 and support the notion that binding of other substrates to the TKBD of CBL may induce partial RING opening.
To determine if the conformational changes observed in the structures occur in solution, we developed a disulfide assay to probe the proximity of the RING and TKB domains (see Supplementary Note and Supplementary  Fig. 2 ). We engineered a disulfide pair with one residue in the RING domain (D435C) and one residue in the TKBD (R139C), such that their Cβs are within 7 Å in the nCBL structure but are widely separated in other CBL complex structures (Fig. 3a) . The constructed npg a r t i c l e s mutant, CBL R139C D435C, is referred to as diCys. Formation of a disulfide bond was monitored by SDS-PAGE, and disulfide-bonded diCys migrated faster than unmodified diCys (Fig. 3b,c) . Wild-type CBL and individual cysteine mutants did not form disulfide bonds. Addition of E2, the ZAP-70 peptide, or both, impaired diCys disulfide bond formation, consistent with the observed increased distances between Arg139 and Asp435 in CBL−S and E2−CBL−S.
RING-TKBD interaction competes against E2 binding
RING residues that maintain the TKBD interaction in nCBL also bind E2 in E2−CBL−S, implying that E2 binding is competitive. To probe the mode of autoinhibition, we introduced TKBD mutations that modify the affinity of the TKBD-RING interaction and assessed their effects. Previous structure-based studies of RING E3−E2 complexes have revealed that RING domains recruit E2s through hydrophobic surfaces, as observed in E2−CBL−S 16, [31] [32] [33] . Each RING contains a critical residue on this surface that decreases E2 binding and hinders E3 activity when mutated 33, 34 . This residue, Ile383, contacts Met222 in nCBL and UbcH7's Ala98 in E2−CBL−S (Fig. 3d) . Substitution of Met222 to phenylalanine or glutamate should respectively enhance or weaken the hydrophobic interactions between the RING and TKBD in the closed conformation, thus modifying the rate of disulfide bond formation. Indeed, phenylalanine substitution enhanced diCys disulfide bond formation, whereas glutamate substitution reduced it (Fig. 3b,c) . Correspondingly, we tested the abilities of M222E and M222F mutants to bind UbcH5B, using surface plasmon resonance (SPR) analysis. The former showed approximately four-fold higher affinity for UbcH5B than for WT CBL, whereas the latter bound UbcH5B with slightly weaker affinity ( Table 2 and Supplementary Fig. 3 ). Met222 forms part of UbcH7's Arg5 binding pocket in E2−CBL−S (Fig. 2b) , so to control for the possibility of unintentional effects of an introduced electrostatic interaction, we mutated the corresponding residue in UbcH5B (Lys4) to alanine. Alanine substitution reduced UbcH5B affinity, but the M222E mutant still showed approximately three-fold higher affinity for UbcH5B K4A than for WT CBL ( Table 2) . Hence disruption of the RING-Met222 interaction augments E2 binding.
To determine whether the RING-TKBD interaction has an inhibitory role on ligase activity, we carried out Michaelis-Menten kinetic analyses on in vitro autoubiquitination assays using full-length M222E and M222F CBL mutants. Only catalytic efficiency (k cat /K m ) was estimated because the reactions were not saturated at the highest achievable UbcH5B~ubiquitin concentration. Compared to WT, CBL M222E showed an ~2.5-fold enhancement in k cat /K m , whereas CBL M222F showed no appreciable difference ( Table 3 and Supplementary  Fig. 4a ). Similar results were obtained using UbcH5B K4A or chainterminating K0-ubiquitin ( Supplementary Fig. 4b,c) . Addition of the ZAP-70 peptide marginally increased the UbcH5B-binding affinity of CBL (Table 2 ) but did not enhance autoubiquitination (Table 3) . Together, these data support an autoinhibitory mechanism in which the E2-binding surface on the RING domain associates with the TKBD to compete against E2 binding and thereby reduce the catalytic efficiency of CBL.
pTyr371 enhances catalytic efficiency
We conducted a kinetic analysis on CBL pY371 autoubiquitination to probe its effects on k cat /K m . Phosphorylation was achieved by coexpression of CBL with a constitutively active Src construct (see Supplementary Methods). Unfortunately, we found trace amounts 
of CBL pY368 that were inseparable from CBL pY371. Despite this, CBL pY371 cocrystallized readily with UbcH5B and the ZAP-70 peptide. To generate homogeneous pY371 for biochemical studies, we mutated Tyr368 to phenylalanine. The structure of CBL Y368F pY371 bound to UbcH5B and the ZAP-70 peptide (E2−pCBL Y368F −S) was nearly identical to E2−pCBL−S ( Table 1 and Supplementary Fig. 5 ). In addition, CBL pY371 and Y368F pY371 had similar kinetic constants for CBL autoubiquitination ( Table 3 and Supplementary Fig. 6) ; hence, Y368F substitution does not affect the structure or activity of CBL pY371.
Notably, both CBL pY371 and Y368F pY371 had an ~1,400-fold enhanced k cat /K m compared to WT ( Table 3) . Quantification of phosphorylation-induced changes in k cat and K m was not possible because the WT ubiquitination reaction could not be saturated; however, for this reaction, our data are consistent with K m and k cat exceeding 43 µM and 0.0029 min −1 , respectively. By comparison, K m (~7 µM) is decreased and k cat (~0.7 min −1 ) is increased for CBL pY371 autoubiquitination; hence, changes in both k cat and K m contribute to the enhanced catalytic efficiency observed for CBL pY371 ubiquitination.
pTyr371 abolishes autoinhibition
In the structures of unphosphorylated CBL, Tyr368 and Tyr371 of LH 'fasten' LH to the TKBD (Supplementary Fig. 7 ) but release it upon Tyr371 phosphorylation (Fig. 1e) . A phosphate moiety on Tyr371 cannot be accommodated in the observed conformation in the unphosphorylated CBL structures; hence, we predicted that pTyr371 abolishes the ability of CBL to adopt the closed conformation. We probed disulfide bond formation of a diCys mutant harboring Y368F pY371 and found that phosphorylation prevented disulfide bond formation (Fig. 3e) , suggesting that CBL no longer adopts the closed conformation. Based on our earlier finding, we also expected an increase in E2 binding with autoinhibitory disruption. Indeed, CBL Y368F pY371 enhanced UbcH5B binding by ~11-fold ( Table 2) , consistent with the decrease in K m for autoubiquitination of CBL Y368F pY371 compared to WT.
Notably, unphosphorylated diCys Y368F formed disulfide bonds more slowly than did diCys (Fig. 3e) . Correspondingly, CBL Y368F marginally promoted UbcH5B binding ( Table 2 ) and showed approximately two-fold enhancement in k cat /K m for CBL autoubiquitination ( Table 3 and Supplementary Fig. 6b ). Based on interactions observed in nCBL, this mutation probably weakens the LH-TKBD interactions and promotes RING opening, thereby augmenting activity. Mutations at Y371 cannot be phosphorylated, and we predicted that phenylalanine substitution might mimic unphosphorylated tyrosine in preserving the closed conformation. We found that WT and CBL Y371F had comparably low catalytic efficiency ( Table 3) ; CBL Y371F, however, had a slightly higher affinity for UbcH5B ( Table 2 ), suggesting that phenylalanine substitution marginally perturbs the LH-TKBD interaction in the closed conformation. Indeed, in our disulfide assay, diCys Y371F formed disulfide bonds more slowly than did diCys (Fig. 3e) . Thus, modifications and mutations to LH disrupt the closed, autoinhibited conformation; mutations such as Y368F and Y371F appear to shift the equilibrium to an open RING conformation, whereas phosphorylation abolishes the ability of CBL to adopt the closed conformation and thereby contributes to activation of CBL's ligase activity by reducing the K m for the reaction.
pTyr371-binding interface enhances E2 binding and activity
Closer inspection of E2−pCBL−S reveals that LH has flipped 180° about LL2 and rotated, thereby initiating contacts with the RING domain and E2 that are not present in E2−CBL−S (Figs. 1 and 4) . In E2−pCBL−S, the C terminus of LH abuts the N-terminal helix of E2. In addition, the tail of the RING domain has shifted to contact the N terminus of LH. Because side chain density was poor in the E2−pCBL−S map, detailed interactions are described on the basis of a higher resolution structure of a complex of UbcH5B and a smaller fragment of phosphorylated CBL, comprising the LHR and RING domains Fig. 4d-f and Supplementary Fig. 5d,e) ; the two structures have an r.m.s. deviation of 1.1 Å for Cα atoms.
Crucial RING-E2 interactions that are seen in E2−CBL−S and other RING−E2 complexes are unchanged 16, 31, 32 (Fig. 4c,f) . pTyr371 does not directly bind UbcH5B but instead sits in a pocket just below the E2-binding surface. The pocket is stabilized by hydrophobic interactions between the aromatic ring of pTyr371 and LL2's Leu370, Met374 and Phe378 and by hydrophilic interactions between the phosphate moiety and Lys382 and Lys389 (Fig. 4f) . New β-strands in LL1 and the C-terminal tail of the RING domain form a β-sheet that stabilizes the binding pocket of pTyr371; the side chain of Val431 from the new RING β-strand forms a hydrophobic interaction with Phe378. Phe434 on the tail of the RING forms hydrophobic interactions with the aromatic group of Y368F.
To assess the importance of the pTyr371-binding interface on E2 binding and activity, we generated two CBL pY371 mutants, Y368F K389A and Y368F V431A, to disrupt hydrogen bonding with the phosphate moiety of pTyr371 and destabilize hydrophobic interactions, respectively (Fig. 4f) . Both mutants bound UbcH5B more weakly ( Table 2 ) than WT and had reduced k cat and higher K m values for CBL autoubiquitination than did CBL Y368F pY371 ( Table 3 and Supplementary Fig. 6a ). To measure binding contributions originating from the pTyr371 LHR-RING conformation, we used the CBL 354-435 fragment containing only the LHR and the RING domain and found that the pTyr371 fragment bound UbcH5B with two-fold higher affinity than did the unphosphorylated counterpart and the fragment harboring a Y371F substitution ( Table 2) . Thus, Tyr371 phosphorylation also transforms the LHR and the RING domain into a new conformation that enhances E2 binding and optimizes k cat for CBL autoubiquitination.
pTyr371 is critical for EGFR ubiquitination
To determine whether abolishing autoinhibition and forming the pTyr371-binding interface are crucial for RTK ubiquitination, we used in vitro and in vivo assays to probe the effects of our mutations on EGFR ubiquitination. Our in vivo assays were carried out with full-length CBL and included EGF-stimulation to promote CBL Tyr371 phosphorylation; the Y371F, K389A and V431A mutants did not contain a Y368F substitution. Consistent with previous findings 8, 20 , CBL Y371F, which cannot abolish autoinhibition or form the pTyr371-binding interface, was defective in both in vitro and in vivo EGFR ubiquitination assays (Fig. 5) . Unphosphorylated CBL Y368F, which partially disrupts autoinhibition, also failed to promote EGFR ubiquitination in vitro. A previous mutagenesis study on the tail region of the RING domain identified Val431 and Phe434 as important residues for EGFR ubiquitination 35 , but the mechanism was not established. CBLs harboring K389A or V431A substitutions and pY371 were defective in EGFR ubiquitination (Fig. 5) . Thus, both 
DISCUSSION
E3s regulate the fates of thousands of targets involved in many cellular processes; hence, precise control of their activity is vital. The E3 activity of c-Cbl, a single-subunit RING E3, is stimulated by Tyr371 phosphorylation, and although prior in vitro and in vivo studies clearly support phosphoregulation of the ligase activity of c-Cbl through this tyrosine 8, 25, 26 , detailed mechanisms for this have been unavailable. Our results reveal an intricate regulation of c-Cbl's ligase activity by autoinhibition, conformational changes and phosphorylation.
As reported previously 36 , we propose a two-state model for the regulation of the activity of c-Cbl (Fig. 6) . When unactivated, unphosphorylated c-Cbl exists in an equilibrium between an open, catalytically competent conformation and a closed, autoinhibited conformation. Phosphorylation of Y371 prohibits c-Cbl from accessing its closed conformation, thereby leading to a relative increase in activity or activated state. In addition, the absence of the LH-TKBD contact enables marked movement of the RING domain, bringing E2 closer (~28 Å) to the TKBD substrate-binding site, where the full-length substrate may bridge the gap. pTyr371 also initiates new interactions within the LHR and RING domain that further enhance E2 binding and optimize ubiquitination activity.
Our kinetic analysis of CBL autoubiquitination shows that pTyr371 massively enhances the catalytic efficiency of CBL by increasing k cat and decreasing K m . The improvement in k cat may be attributed to E2~ubiquitin positioning and optimization of the chemical environment of the active site of UbcH5B in an analogous manner to that done by Nedd8-modified CRL 37 . When unactivated, residues 354−359 of LL1 do not make contact with other regions of CBL, but their conformation is restricted by LH-TKBD interactions. Upon disruption of these interactions by pTyr371, this region may become flexible and promote juxtaposition of the RING domain and E2~ubiquitin with lysines on CBL and on ubiquitin moieties of ubiquitinated CBL. Based on the 11-fold improvement in UbcH5B binding, we estimate that pTyr371 may improve the k cat for CBL autoubiquitination at most by ~120-fold. A decrease in K m value probably arises from enhancements observed in E2 binding due to elimination of autoinhibition and formation of the pTyr371-binding interface. Our data suggest that CBL Y368F pY371 has a stronger binding affinity for UbcH5B~ubiquitin, the actual substrate, than UbcH5B: for any reaction, K m is greater than K d and approaches K d only when the enzyme is in rapid equilibrium with the substrate. In our assay, the K m for CBL Y368F pY371 autoubiquitination (7.7 µM; Table 2) , consistent with the minimal structural changes in the ZAP-70 peptide binding site observed in CBL−S, E2−CBL−S and E2−pCBL−S. Currently, it is not known whether Tyr371 phosphorylation is a strict requirement for ubiquitination of every target. When unactivated, c-Cbl retains a low activity, where target ubiquitination can still occur in vitro, albeit at a much slower rate (Fig. 5b) . Our results and previous Tyr371 mutational studies show that activated c-Cbl is required for ubiquitination of RTKs, Src and TRAIL receptors 8, [20] [21] [22] 39, 40 . c-Cbl recruits targets through different modular domains, and hence the location of target relative to the RING domain changes. Whether both states have preferences for target ubiquitination remains to be investigated.
A number of studies have identified mutations within c-Cbl's LHR and the RING domain in people with myeloproliferative diseases; several of these mutations are sufficient to induce cell transformation (reviewed in ref. 24) . Our data, together with the existing c-Cbl structure 16 , provide new insights into how mutations-particularly in the LHR-can deregulate the activity of c-Cbl ( Supplementary  Fig. 8 ). Mutations that perturb LH-TKBD interactions might change activity of the unactivated state by shifting the equilibrium. pTyr371-binding interface mutations might prevent proper ubiquitination of targets by impeding optimal ligase activity or exposing pTyr371 to rapid dephosphorylation. LHR mutations or deletions have the potential to affect the spatial arrangement of the RING domain and thus target ubiquitination in both states. How these mutations contribute to oncogenicity requires further investigation.
Autoinhibition is a common mechanism in enzyme regulation 41 . Our data reveal a new autoinhibitory mechanism, in which the E2-binding surface of the RING domain is blocked in a competitive manner. Prior to our study, it was not known whether the hydrophobic E2-binding surface on the RING domain could recognize other structural elements npg a r t i c l e s beside E2s. U-box E3s are structurally related to RING E3s and recruit E2s through a similar hydrophobic surface. CHIP U-box E3 is an asymmetric dimer in which the E2-binding surface of one U-box domain is occluded while the other binds an E2 (ref. 42) ; no evidence suggests that the occluded site becomes functional in binding an E2, whereas in c-Cbl, autoinhibition through the E2-binding surface is labile. Increasing numbers of RING E3s have been shown to be regulated by autoinhibition through different mechanisms 37, [43] [44] [45] [46] [47] . We anticipate that future studies will reveal whether targeting the E2-binding surface of a RING domain through intra-or intermolecular interactions may be a common strategy in the regulation of RING E3s. We present the first molecular mechanism describing how phosphorylation regulates single-subunit RING E3 activity. Phosphorylation disrupts the LH-TKBD interaction, preventing c-Cbl from adopting any conformation accessible in the unactivated state. Other classes of E3s use similar regulatory mechanisms; for example, phosphorylation also promotes activity in the HECT E3 Itch by releasing the catalytic domain from autoinhibitory interactions 48 ; for Smurf2, another HECT E3, binding of a partner protein performs the same function 49 , and in CRL, post-translational modification with Nedd8 prevents inhibition by Cand1 (refs. 47, 50) . Phosphorylation also promotes flexibility and induces additional conformational changes that are essential for regulation of the E3 activity of c-Cbl. When Tyr371 is unmodified, the RING domain is spatially restricted to regions distal from the TKBD substratebinding site. Phosphorylation facilitates LHR conformational changes that enable the RING domain to approach the TKBD substrate-binding site. Given that Nedd8 modification of CRL also frees the Rbx1 RING domain to sample multiple orientations that are important for substrate polyubiquitination 47 , we speculate that restricting and freeing the RING domain may be a general mechanism for regulating other RING E3s.
In conclusion, our results elucidate mechanisms for RING autoinhibition and phosphorylation-dependent activation of a single-subunit RING E3 and are supported by recent findings on Cbl-b 51 . These features may serve as a new paradigm for understanding the regulation of other RING E3s and modular enzymes.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nsmb/. Accession codes. Coordinates and structure factors for the crystal structures of nCBL, CBL−S, E2−pCBL−S, E2−pCBL Y368F −S and E2−pCBL LHR-RING are deposited in the Protein Data Bank under accession codes 2Y1M, 2Y1N, 4A4C, 4A4B and 4A49, respectively.
